Neuroendocrine Tumors  >>  Perjeta (pertuzumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Perjeta (pertuzumab) / Roche
NCT00947167: A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Terminated
2
4
US
pertuzumab, 2C4, Omnitarg, Genentech, erlotinib, Tarceva, Erlotinib hydrochloride
Pamela L. Kunz, Genentech, Inc.
Neuroendocrine Tumors, Carcinoid Tumors, Adrenal Gland Tumors, Neuroblastoma, Pancreatic Neuroendocrine Tumors, Multiple Endocrine Neoplasia
05/10
05/10
NCT01121939: Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

Checkmark P2 data-ASCO
Jun 2012 - Jun 2012: P2 data-ASCO
Completed
2
43
US
Bevacizumab, Avastin, Pertuzumab, Omnitarg, 2C4, Sandostatin LAR® Depot, Octreotide
SCRI Development Innovations, LLC, Genentech, Inc.
Neuroendocrine Carcinoma
02/15
08/15

Download Options